Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset - HMS LINCS Database

Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)

Filter results: >>>>

Cell	Small Molecule	Primary Target	Pathway	GR50	GRmax	GR_AOC	Death_AUC	GR Hill Coefficient	GEC50	GR r2
BT-20	Ipatasertib	AKT	PI3K/mTOR	0.64483	0.1015	0.3111	0.0476	0.7459	0.59909	0.98219
BT-20	Alpelisib	PI3Ka	PI3K/mTOR	2.0326	-0.1181	0.2014	0.0639	0.8192	7.7705	0.99071
BT-20	Taselisib	PI3Ka, g, d	PI3K/mTOR	0.018077	-0.3749	0.7363	0.2005	0.7541	0.028401	0.95352
BT-20	TGX221	PI3Kb	PI3K/mTOR	Inf	1.0152	-0.0415	-0.0034	0.0000	Inf	-7.4504
BT-20	Torin2	mTOR/ATM/ATR	PI3K/mTOR	0.008897	-0.2891	0.5365	0.1367	0.8675	0.012533	0.97198
BT-20	Everolimus	mTOR1	PI3K/mTOR	Inf	0.3900	0.5932	0.0889	0.0000	Inf	0.031152
BT-20	INK-128	mTORC1/2	PI3K/mTOR	0.012881	-0.0045	0.5675	0.1137	1.3697	0.01193	0.99574
BT-20	PF-4708671	p70S6K	PI3K/mTOR	15.1446	0.6601	0.0129	0.0102	1.1942	37.9666	0.89476
BT-20	Buparlisib	pan PI3K	PI3K/mTOR	0.63756	-0.5514	0.3662	0.1474	1.2077	1.2887	0.99431
BT-20	Pictilisib	pan PI3K	PI3K/mTOR	0.90394	-0.1650	0.2960	0.0736	0.9819	1.5458	0.99177
BT-20	Ceritinib	ALK	RTK	1.5315	-0.7365	0.2591	0.1255	1.7439	2.7905	0.99717
BT-20	Neratinib	EGFR/HER2	RTK	1.2826	0.3026	0.1496	0.0391	0.6768	2.19	0.97744
BT-20	Tivantinib	MET	RTK	0.47342	-0.4883	0.4183	0.1893	2.5782	0.60346	0.99447
BT-20	Cediranib	VEGFR/cKIT	RTK	5.6982	0.2210	0.0383	0.0150	2.7852	5.3221	0.97585
BT-20	Cabozantinib	VEGFR2/MET	RTK	5.3516	-0.2030	0.0566	0.0432	4.9846	5.8613	0.99079